STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation. - Wikidata - thesis-toulmin - TriplyDB

STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation.

STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation.

http://www.wikidata.org/entity/Q36917725

about

The host STING pathway at the interface of cancer and immunity cGAS is essential for the antitumor effect of immune checkpoint blockade.Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways The role of myeloid cells in cancer therapies.Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing.Innate immune mediators in cancer: between defense and resistance.Innate immune signaling and regulation in cancer immunotherapy.Crosstalk between Cytoplasmic RIG-I and STING Sensing Pathways.Rationale for stimulator of interferon genes-targeted cancer immunotherapy.Nucleic acid sensing pattern recognition receptors in the development of colorectal cancer and colitis.cGAS-STING Activation in the Tumor Microenvironment and Its Role in Cancer Immunity.Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy.Stimulating Innate Immunity to Enhance Radiation Therapy-Induced Tumor Control.cGAS/STING Pathway in Cancer: Jekyll and Hyde Story of Cancer Immune Response.Immunological landscape of consensus clusters in colorectal cancer.Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade.IDO1 in cancer: a Gemini of immune checkpoints.Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences.Integration of nano drug-delivery system with cancer immunotherapy.Chemo-Immunotherapy: Role of Indoleamine 2,3-Dioxygenase in Defining Immunogenic Versus Tolerogenic Cell Death in the Tumor Microenvironment.Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'.Targeting Cytosolic Nucleic Acid-Sensing Pathways for Cancer Immunotherapies.Sexual Dimorphism of Immune Responses: A New Perspective in Cancer Immunotherapy.Hypoxia enhances indoleamine 2,3-dioxygenase production in dendritic cells.Radiation Therapy Combined with Cowpea Mosaic Virus Nanoparticle in Situ Vaccination Initiates Immune-Mediated Tumor Regression.Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions.

P2860

Q37042237-F1019A4E-E5C9-4937-9EFD-062F33B3C107 Q37658955-8DA8DB58-CF69-44D3-808A-473969FD4FA7 Q37690959-1E6B80D2-08A0-450B-92C6-AA4211DFEA63 Q38875474-68E0818C-7A69-40FC-A8DA-457BFE500F5F Q38959510-E539FA2D-9F86-4383-A28A-B03CA3ECCD33 Q38991015-96216736-F581-4A3A-ACF4-061F30A81FFD Q39041026-95C55357-E6CC-431B-88F9-0CB2BC77FBE8 Q39078459-DDCAE69E-9BFC-49BC-99C6-F00B65E33038 Q39144454-4843A9D6-1A61-4D98-B6A1-75800731C0A3 Q39146122-325CF17E-8D70-4CA4-A549-E33CC3CF6FFC Q41997059-A859F690-FF57-4218-A7B3-0F560095BB75 Q42378527-36C79807-832C-4C7C-8FD2-635E5CAA0A6F Q46189367-59371D64-7C0B-4757-92ED-D843731614E4 Q47132136-97419064-1CB0-46F7-9288-B8B224E317E9 Q47148210-1A18571D-08A2-447E-8BE3-7271454F5199 Q47391699-7D3BF90E-F62F-429C-B6AE-4379C05079B2 Q47836812-DEE42613-DAFF-49B0-AF5B-C2B298FF9573 Q48306002-EC2F0290-2656-4DBC-BDE9-2D78C29FF64E Q48622958-CF2684C6-E316-4546-B7FA-C29C64B9BBB1 Q49592881-151A0F81-0AB1-4784-9681-C5C24E54274D Q50138585-EC8BEB49-FFF2-4D23-9921-1CBBD0688FBF Q52568331-E8E0128C-B95F-426C-B40A-E8E0AC709230 Q52606149-E355B009-84D8-4CE9-8FC3-5B08E7EE6CD4 Q53701710-8DAF152D-CF94-414F-A473-D5960ECE5818 Q55231623-BC0EAC45-BCFE-48A3-BBA2-E02FFDB4A07A Q55287125-F587D574-D4AB-4045-B15B-75DA71A00ED8

P2860

STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation.

http://www.wikidata.org/entity/Q36917725

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation.

@en

type

label

STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation.

@en

prefLabel

STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation.

@en

P1433

Q36917725-E4EAE884-FB05-488E-87FF-C9C744650DE3

P1476

Q36917725-79E74890-0765-47FE-8B39-5231498AA806

P2093

Q36917725-287664E8-76F9-4720-B2E7-71B7D6DA0626

Q36917725-A572D2A1-FC56-400F-919A-801A8DD6E319

Q36917725-B56282B5-A6A4-4F64-A2C3-67056CBBF905

Q36917725-E24C34AD-2332-4D94-95EB-B32557902E0F

Q36917725-E54CDEA9-639F-49EF-BF47-A668B6BD33C6

Q36917725-FB20738C-6AF1-4771-A01F-FCEEBCA5EA48

P2860

Q36917725-3A4FCE56-4310-4C53-AA10-E7B0154FF6F5

Q36917725-3BC48CF6-6239-40B5-963C-929E7905F650

Q36917725-60FF9844-2968-4236-A03C-D26C322DE784

Q36917725-779CB2CC-E64C-4402-BFB0-30A169E072FD

Q36917725-7847941D-CCB8-40E8-9263-574373866E5F

Q36917725-7C7A25FF-2146-4859-8C9D-C17FF268940B

Q36917725-80CC15ED-F45E-449E-B3EE-8196FB4BC75E

Q36917725-885CBF82-C046-4724-A153-93D76797D933

Q36917725-8EB4AA44-2EBD-4718-8CE7-E51CF1E4ADB0

Q36917725-AA7F71D7-1085-4AED-ADDE-C029BEB46A56

P304

Q36917725-B06864B7-5453-44EB-8162-7F3F0A2CD45A

P31

Q36917725-672820E1-A89C-4877-B8EC-8EF1702BFD4D

P356

Q36917725-AA4B1220-9925-4B18-94CB-DD961CE7BCE4

P407

Q36917725-DAED3467-5081-4760-9610-F0D6A07436C7

P433

Q36917725-FF2EB5BE-9725-469B-A88A-D0375E3CDB3B

P478

Q36917725-AAEB942D-8787-489E-88AF-595321C6CECC

P50

Q36917725-F5D1C177-56DC-4431-B618-7F44C1591C38

Q36917725-FB65EF7F-F651-43DC-A0DE-1E660B5BD03A

P577

Q36917725-1B87C128-AED2-4626-AB7D-EC9CE9ADB878

P5875

Q36917725-51CAD93C-0C8F-4B51-8EF6-D8B9794591AD

P698

Q36917725-D10A5110-D89C-408C-BA48-4E64B6682025

P932

Q36917725-94B215D2-381C-4FDF-AC1D-BA8BD518E314

P356

0008-5472.CAN-15-1456

P1433

Cancer Research

P1476

STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation.

@en

P2093

Ali S Arbab

http://www.w3.org/2001/XMLSchema#string

Andrew L Mellor

http://www.w3.org/2001/XMLSchema#string

Eslam Mohamed

http://www.w3.org/2001/XMLSchema#string

Gabriela Pacholczyk

http://www.w3.org/2001/XMLSchema#string

Henrique Lemos

http://www.w3.org/2001/XMLSchema#string

Rong Ou

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

Activation of the STING adaptor attenuates experimental autoimmune encephalitis.

Indoleamine 2,3 dioxygenase and metabolic control of immune responses.

Neoantigens in cancer immunotherapy.

Suppression of systemic autoimmunity by the innate immune adaptor STING.

STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity.

Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease

Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.

Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase

P304

2076-2081

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-15-1456

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-03-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

297744121

http://www.w3.org/2001/XMLSchema#string

P698

26964621

http://www.w3.org/2001/XMLSchema#string

P932

4873329

http://www.w3.org/2001/XMLSchema#string